BridGene Biosciences to Participate in Virtual H.C. Wainwright BioConnect and BIO Partnering @ JPM during "J.P. Morgan Week 2022"

SAN JOSE, Calif.: SAN JOSE, Calif., Jan. 5, 2022 /PRNewswire/ -- BridGene Biosciences, Inc., a biotechnology company using a unique chemoproteomic technology to discover and develop small molecules for high value, traditionally undruggable targets, announced today that the company is participating in H.C. Wainwright BioConnect and BIO Partnering @ JPM....

Click to view original post